Publication
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerGastrointestinal Stromal Tumorcivic_curation1.00
- drugRegorafenib Anhydrouscivic_curation1.00
- geneBRAFcivic_curation1.00
- geneKITcivic_curation1.00
- variantBRAF Exon 15 Mutationcivic_curation1.00
- variantKIT D820Ycivic_curation1.00
- variantKIT Exon 11 Mutationcivic_curation1.00
- variantKIT Exon 9 Mutationcivic_curation1.00
- variantKIT N822Kcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22614970
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF Exon 15 Mutation1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | C | Supports Resistance | 1 | accepted | EID4605This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC | civic |
| KIT D820Y1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID4589This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC | civic |
| KIT Exon 11 Mutation1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID4629This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments wi… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC | civic |
| KIT Exon 9 Mutation1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | B | Supports Reduced Sensitivity | 2 | accepted | EID4139This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments wi… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC | civic |
| KIT N822K1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID4595This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC | civic |